NASDAQ$SGMO
Sangamo Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported business highlights and financial results, including data supporting neurology pipeline advancement.
Sangamo Therapeutics reported its Q4 and full year 2023 financial results, highlighting the prioritization of its neurology pipeline and progress with novel AAV capsid delivery technology. The company is seeking partnerships for its Fabry disease program and anticipates pivotal data read-out for its Hemophilia A collaboration with Pfizer in mid-2024.
- Data from novel proprietary neurotropic AAV delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier penetration in non-human primates.
- Chronic neuropathic pain and prion disease preclinical programs advance, with IND and CTA submissions expected in the fourth quarters of 2024 and 2025, respectively.
- FDA aligned on an abbreviated pathway to potential approval, and EMA granted PRIME eligibility for isaralgagene civaparvovec in Fabry disease.
- Pfizer anticipates BLA and MAA submissions for Hemophilia A collaboration by early 2025 if the pivotal readout is supportive.
Headline financials
Revenue & EPS history
Sangamo · Revenue · Quarterly
$2.04M
Forward guidance
Sangamo expects total operating expenses in the range of approximately $145 million to $165 million in 2024 on a GAAP basis. Non-GAAP total operating expenses, excluding stock-based compensation and depreciation and amortization, are expected to be in the range of approximately $125 million to $145 million in 2024, subject to additional funding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
+0.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
-3.2%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+59.1%
Q1 2017
Best reaction
-39.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -1.3% | -12.0% | — | |
| Q1 2026 | +3.4% | -5.0% | +10.4% | |
| Q3 2025 | -16.1% | -9.1% | -9.1% | |
| Q2 2025 | -5.6% | +12.5% | +14.6% | |
| Q1 2025 | -39.1% | -37.3% | -33.3% | |
| Q4 2024 | -16.2% | -13.9% | -29.7% | |
| Q3 2024 | -9.6% | -24.1% | -29.3% | |
| Q2 2024 | +11.6% | +32.5% | -2.6% | |
| Q1 2024 | +11.7% | +14.0% | +14.0% | |
| Q4 2023 | -9.4% | -1.2% | -37.2% | |
| Q3 2023 | -27.0% | -30.2% | -28.6% | |
| Q2 2023 | -10.3% | -7.7% | -18.8% | |
| Q1 2023 | -0.6% | -6.2% | -21.7% | |
| Q4 2022 | +2.8% | +4.2% | -41.5% | |
| Q3 2022 | -15.0% | -19.0% | -14.3% | |
| Q2 2022 | +8.3% | +9.2% | +15.2% | |
| Q1 2022 | -9.6% | -15.5% | -18.8% | |
| Q4 2021 | +9.7% | +9.3% | +6.9% | |
| Q3 2021 | +20.0% | +14.2% | -11.4% | |
| Q2 2021 | +3.2% | +7.0% | +6.6% | |
| Q1 2021 | -10.7% | -9.4% | -7.4% | |
| Q4 2020 | -9.2% | -2.8% | -2.7% | |
| Q3 2020 | +12.6% | +8.7% | -6.2% | |
| Q2 2020 | +2.4% | +9.1% | -12.3% | |
| Q1 2020 | +12.5% | +15.4% | +27.1% | |
| Q4 2019 | +27.5% | +21.9% | -4.9% | |
| Q3 2019 | -1.3% | +3.4% | +23.3% | |
| Q2 2019 | +1.1% | -5.2% | -10.3% | |
| Q1 2019 | -14.8% | -13.5% | -15.6% | |
| Q4 2018 | +7.8% | +8.2% | +2.4% | |
| Q3 2018 | -22.0% | -24.5% | -20.9% | |
| Q2 2018 | +8.9% | +13.2% | -2.1% | |
| Q1 2018 | -5.8% | -5.5% | +1.2% | |
| Q4 2017 | +12.4% | +5.6% | -2.0% | |
| Q3 2017 | +12.6% | +7.9% | +41.4% | |
| Q2 2017 | +9.2% | +33.3% | +54.6% | |
| Q1 2017 | +59.1% | +90.9% | +65.9% | |
| Q4 2016 | +9.3% | +10.5% | +9.3% | |
| Q3 2016 | +2.7% | -2.7% | -4.1% | |
| Q2 2016 | -26.0% | -26.9% | -34.2% | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | -11.7% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | -17.4% | — | — | |
| Q1 2015 | +7.9% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2014 | +1.4% | — | — | |
| Q2 2014 | +4.4% | — | — | |
| Q1 2014 | -9.4% | — | — | |
| Q4 2013 | +3.5% | — | — | |
| Q3 2013 | +4.6% | — | — | |
| Q2 2013 | +2.9% | — | — | |
| Q1 2013 | +11.3% | — | — | |
| Q4 2012 | +7.6% | — | — | |
| Q3 2012 | -2.6% | — | — | |
| Q2 2012 | -0.8% | — | — | |
| Q1 2012 | +5.1% | — | — | |
| Q4 2011 | -2.6% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +2.7% | — | — | |
| Q4 2010 | -3.4% | — | — | |
| Q3 2010 | +2.9% | — | — | |
| Q2 2010 | -1.8% | — | — | |
| Q1 2010 | -12.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro